Exact Sciences to Participate in J.P. Morgan Healthcare Conference
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Bank of America Co. from $75.00 to $72.00. They now have a "buy" rating on the stock.
Bladder Cancer Detection Kit Market to Hit USD 2.99 Billion by 2032, Driven by Advancements in Non-Invasive Technologies | Research by SNS Insider [Yahoo! Finance]
AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates [Yahoo! Finance]
Exploring High Growth Tech Stocks in December 2024 [Yahoo! Finance]